


U 7444506



THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME;

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office

October 24, 2013

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM
THE RECORDS OF THIS OFFICE OF:

U.S. PATENT: 8,518,987

ISSUE DATE: August 27, 2013

By Authority of the
Under Secretary of Commerce for Intellectual Property
and Director of the United States Patent and Trademark Office

T. LAWRENCE
Certifying Officer





US008518987B2

(12) **United States Patent**
Vermeersch et al.(10) **Patent No.:** US 8,518,987 B2
(45) **Date of Patent:** Aug. 27, 2013

- (54) **PSEUDOPOLYMORPHIC FORMS OF A HIV PROTEASE INHIBITOR**
- (75) **Inventors:** Hans Wim Pieter Vermeersch, Ghent (BE); Daniel Joseph Christiaan Thone, Beerse (BE); Luc Donne Marie-Louise Janssens, Malle (BE); Piet Tom Bert Paul Wigerinck, Terhagen (BE)
- (73) **Assignee:** Janssen R&D Ireland, Little Island, Co. Cork (IE)
- (*) **Notice:** Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 276 days.

(21) **Appl. No.:** 12/536,807(22) **Filed:** Aug. 6, 2009(65) **Prior Publication Data**

US 2010/0204316 A1 Aug. 12, 2010

Related U.S. Application Data

- (62) Division of application No. 10/514,352, filed as application No. PCT/EP03/50176 on May 16, 2003, now Pat. No. 7,700,645.

(30) **Foreign Application Priority Data**

May 16, 2002 (EP) 02076929

- (51)
- Int. Cl.**
-
- A61K 31/353 (2006.01)

- (52)
- U.S. Cl.**
-
- USPC 514/456; 549/396

- (58)
- Field of Classification Search**
-
- USPC 514/456; 549/396
-
- See application file for complete search history.

(56) **References Cited****U.S. PATENT DOCUMENTS**

5,413,999	A	5/1995	Vacca et al.	
6,071,916	A	6/2000	Askin et al.	
6,096,779	A	8/2000	Chikaraishi et al.	
6,248,775	B1	6/2001	Vazquez et al.	
6,281,367	B1	8/2001	Al-Farhan et al.	
6,287,693	B1	9/2001	Savoit et al.	
7,700,645	B2	4/2010	Vermeersch et al.	
2013/0029945	A1*	1/2013	Phull et al.	514/158

FOREIGN PATENT DOCUMENTS

EP	0715618	B1	6/1996	
JP	05-230044		9/1993	
WO	WO 95/06030	A1	3/1995	
WO	WO 98/56781		12/1998	
WO	WO 99/51618		10/1999	
WO	WO 99/67254		12/1999	
WO	WO 99/67417	A2	12/1999	
WO	WO 00/29390		5/2000	
WO	WO 00/47551		8/2000	
WO	WO 03/106461	A1	12/2003	

OTHER PUBLICATIONS

Seddon "Pseudopolymorph/\..." Crystal Growth & design v.4(6) p. 1087 (2004) (2 pages from internet).*

Gysegem et al. "Solid state chara . . ." AAOS Annual meeting abs. (2009).*

Gao "Physical chemical . . ." AAPS PharmSci. 3(1) p. 1-8 (2001).*

Gysegem "Solid state . . ." Eu. J.Pharm. Sci. 38 p. 489-497 (2009).*

Vermeersch "Pseudopo . . ." CA140:47540 (2003).*

International Search Report re: PCT/EP03/50176, dated May 16, 2003.

Giron D., et al., "Thermal analysis and calorimetric methods in the characterization of polymorphs and solvates," *Thermochimica Acta*, Elsevier Science Publishers, Amsterdam, vol. 243, 1995, pp. 1-59.Borka L., et al., "Crystal polymorphism of pharmaceuticals," *Acta Pharmaceutica Jugoslavica, Savez Farmaceutskih Drustava Jugoslavije, Zagre, Yu*, vol. 40, 1990, pp. 71-94.Ghosh a.K., et al., "Potent HIV protease inhibitors incorporating high-affinity P2-ligands and (R)-(hydroxyethylamino) sulfonamide isostere," *Bioorganic & Medical Chemistry Letters*, Oxford, GB, vol. 8, No. 6, Mar. 17, 1998, pp. 687-690.Grunenber A., et al., "Theoretical derivation and practical application of energy/temperature diagrams as an instrument in preformulation studies of polymorphic drug substances," *International Journal of Pharmaceutics* 129 (1996) 147-158.

Byrn, S. R., et al., "Solid-State Chemistry of Drugs", Second Edition, 1999, published by SSCI, Inc., pp. 12-13.

Seddon, K., *Crystal Growth & Design*, 4 (6), p. 1087 (2004).Braga, D., et al. "Making Crystals from Crystals: A Green Route to Crystal Engineering and Polymorphism", *Chem. Commun.*, pp. 3635-3645 (2002).

Kirk-Othmer Encyclopedia of Chemical Technology, "Crystallization", vol. 8 (2002) pp. 95-147 (2002).

Vermeersch, H., et al. "Pseudopolymorphic Forms of a HIV Protease Inhibitor", *Caplus No. 1006987* (2003).

"Defendants Lupin Limited's, Lupin Pharmaceuticals, Inc.'s, Mylan Pharmaceuticals Inc.'s and Mylan Inc.'s Joint Invalidation Contentions Pursuant to Local Patent Rule 3.6(b)", in the United States District Court District of New Jersey, Consolidated Civil Action No. 10-5954-WHW-MCA, Nov. 18, 2011 (Redacted), 178 pages.

"Hetero Drugs, Ltd.'s Certification of Non-Infringement and/or Invalidation of United States Patent Nos. 5,843,946, 6,037,157, 6,248,775, 6,335,460, 6,703,403, 7,470,506, and 7,700,645", Feb. 10, 2011 (Redacted), 73 pages.

"Lupin Ltd.'s Notification of Certification of U.S. Patent Nos. 6,037,157, 6,703,403, 7,470,506, and 7,700,645 Pursuant to § 505(j)(2)(B)(iv) of the Federal Food, Drug, and Cosmetic Act", Jun. 3, 2011 (Redacted), 96 pages.

"Teva Pharmaceuticals USA, Inc.'s and Teva Pharmaceutical Industries, Ltd.'s Invalidation Contentions Under Local Patent Rules 3.3 and 3.6", Nov. 18, 2011 (Redacted), 123 pages.

Ansel et al., "Pharmaceutical Dosage Forms and Drug Delivery Systems", Lippincott Williams & Wilkins, 7th ed., 1999, 297-304.Bauer, "Ritonavir an Extraordinary Example of Conformational Polymorphism", vol. 18, *Pharmaceutical Res.*, 2001, 859-866.

Berstein, J., "Polymorphism in Molecular Crystals", Oxford University Press, pp. 4-8, 2002.

Brittain, H.G., "Polymorphism in Pharmaceutical Studies", *Discovery Laboratories, Inc.*, 1999, pp. 205-208.Byrn, S. et al., *Pharmaceutical Solids A Strategic Approach to Regulatory Considerations*, *Pharmaceutical Res.*, vol. 12, No. 7, 1995, 945-954.

(Continued)

Primary Examiner — Celia Chang(74) *Attorney, Agent, or Firm* — Woodcock Washburn LLP(57) **ABSTRACT**

New pseudopolymorphic forms of (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl (1S,2R)-3-[[[4-aminophenyl)sulfonyl] (isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamate and processes for producing them are disclosed.

19 Claims, 18 Drawing Sheets

(56)

References Cited

OTHER PUBLICATIONS

Center for Drug Evaluation and Research, "Guideline for Submitting Supporting Documentation in Drug Applications for the Manufacture of Drug Substances", Feb. 1987, 20 pages.

Chemburkar, S.R. et al., "Dealing with the Impact of Ritonavir Polymorphs on the Late Stages of Bulk Process Development", Organic Process Research and Development, vol. 4, No. 5, 2000, pp. 413-417.

Chikaraishi, Y. et al., "Preparation of Piretanide Polymorphs and Their Physicochemical Properties and Dissolution Behaviors", Chem. Pharm. Bull., vol. 42(5), May 1994, pp. 1123-1128.

Datta, S. et al., "Crystal structures of drugs: advances in determination, prediction, and engineering", Nature Reviews Drug Discovery, vol. 3, Jan. 2004, pp. 42-57.

Ghosh et al., "Structure Based Design: Novel Spirocyclic Ethers as Nonpeptidic P₂-Ligands for HIV Protease Inhibitors", Bioorganic and Med. Chem. Letters 8, Feb. 1998, 687-90.

Haleblian, J. et al., "Pharmaceutical Applications of Polymorphism", J. Pharm. Sci. vol. 64, No. 8, Aug. 1975, pp. 1269-1288.

ICH Harmonized Tripartite Guideline, "Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances, Q6A", Oct. 6, 1999, 35 pages.

Jesley, et al., "Organic Phase Analysis, II. Two Unexpected cases of Pseudopolymorphism", Arch. Pharm. Chem. Sci. Ed., vol. 9, May 1981, 123-130.

Johnson et al., "Indinavir Sulfate" Analytical Profiles of Drug Substances and Excipients, vol. 26, Academic Press, 1999, 319-357.

Jozwiakowski, Water-Insoluble Drug Formation; Chapter 15: Alteration of the Solid State of the Drug Substance: Polymorphs, Solvates, and Amorphous Forms, Interpharm Press, Jan. 5, 2001, 525-568.

Matsuda et al., "Physicochemical Characterization of Sprayed-Dried Phenylbutazone Polymorphs", J. Pharm. Sci., vol. 73, No. 2, Feb. 1984, pp. 173-179.

McCrone, W.C., "Physics and chemistry of the Organic Solids State; Chapter 8: Polymorphism", vol. 2, eds. D. Fox, M.M. Labes, and A. Weissberger, Wiley Interscience, New York, 1965, 725-767.

Salole, E.G., "The Physicochemical Properties of Oestradiol", J. Pharm. Biomed. Anal., vol. 5, No. 7, 1987, pp. 635-648.

Ghosh, et al., Nonpeptidic P₂ Ligands for HIV Protease Inhibitors: Structure-Based Design, Synthesis, and Biological Evaluation, J. Med. Chem., 39, 1996, 3278-3290.

European Patent Application No. 10180831.9: Extended European Search Report dated Feb. 28, 2011, 8 pages.

Japanese Patent Application No. 513292/04: Official Action dated Sep. 1, 2009, 3 pages.

Ogata, "Operation of Chemical Experiment Procedures," K.K. Nankodo, 1963, 367-377 and 297-399.

Lupin's Detailed Factual and Legal Basis for Lupin's Paragraph IV Certification that U.S. Patent Nos. 6,037,157; 6,703,403; 7,470,506, and 7,700,645 are Invalid, Unenforceable, and/or Not Infringed, Oct. 1, 2010, 96 pages, Redacted.

Mylan's Paragraph IV Certification that U.S. Patent Nos. 7,470,506 and 7,700,645 are Invalid, Unenforceable, and/or Not Infringed, Oct. 1, 2010, 38 pages, Redacted.

Plaintiff's Response to Invalidity Contentions of Defendants Lupin Limited, Lupin Pharmaceuticals, Inc., Mylan Pharmaceuticals Inc., and Mylan Inc. Concerning U.S. Patent No. 7,700,645 Pursuant to Local Patent Rules 3.4A and 3.6(i), Mar. 29, 2012, 62 pages.

Plaintiff's Response to Invalidity Contentions of Defendants Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries, Ltd. Concerning U.S. Patent No. 7,700,645 Pursuant to Local Patent Rules 3.4A and 3.6(i), Mar. 29, 2012, 51 pages.

* cited by examiner




FIG. 2




FIG. 3

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.